Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00407342
Recruitment Status : Completed
First Posted : December 5, 2006
Last Update Posted : September 30, 2009
Information provided by:
Medical University of Graz

December 4, 2006
December 5, 2006
September 30, 2009
February 2004
June 2004   (Final data collection date for primary outcome measure)
Modified PASI (Psoriasis area and severity index) [ Time Frame: 6 months ]
Modified PASI (Psoriasis area and severity index)
Complete list of historical versions of study NCT00407342 on Archive Site
  • VAS for therapeutic effect; [ Time Frame: 6 months ]
  • VAS for severity of skin lesions [ Time Frame: 6 months ]
  • VAS for therapeutic effect;
  • VAS for severity of skin lesions
Not Provided
Not Provided
Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.
Prospective, Randomized Half-side Comparison of Alefacept (Amevive) With or Without UVB-311nm Phototherapy in Patients With Psoriasis (Translated From German)

Alefacept is a new anti-psoriatic drug within the group of the so-called biologics. In about 30% of patients alefacept induces a more than 75% improvement of psoriasis after a 12-week treatment period. The start of anti-psoriatic effect by alefacept is delayed, however improvement of psoriatic lesions outlasts the end of alefacept treatment.

Narrowband UVB (UVB-311nm) phototherapy is an established anti-psoriatic treatment regimen with rapid onset of anti-psoriatic efficacy but disease-free intervals after the end of successful treatment courses may be short.

Therefore, in this half-side (left/right side) comparison study we aim to investigate whether an additional narrowband UVB treatment accelerates and improves the anti-psoriatic treatment effects of alefacept.

Psoriasis is an inflammatory skin disease that affects an estimated 2% to 3% of the world's population. There are a wide range of local and systemic clinical treatments and agents for clearing, or at least reducing the expression of, psoriatic skin lesions. There is a new generation of antipsoriatic drugs that specifically target T-cell mediated inflammatory pathways and that are approved for the treatment of moderate to severe psoriasis in the United States. Alefacept (Amevive) is one of these so-called biologics. Alefacept appears to have several advantages over other systemic antipsoriatic agents and is very well tolerated by patients. Weekly administration of alefacept for 12 weeks reduced the psoriasis area and severity index (PASI) by greater than 75% in 30% of patients. The maximal antipsoriatic effect, however, apparently occurs after the 12-week course has ended. In vitro studies and previous case reports suggested that alefacept's antipsoriatic effect may be augmented when it is administered in combination with UVB. These findings prompted us to conduct a prospective randomized half-body comparison study, in which we ask whether the clinical response of psoriatic lesions to alefacept could be improved by combining alefacept with standard UVB 311nm phototherapy.

Comparison: Psoriatic patients are treated with intravenous alefacept once per week for 12 weeks. One randomized chosen body-half (left or right side) is additionally treated with narrowband UVB (UVB-311nm) three times per week until complete clearance of psoriatic lesions at the UV-treated side. PASI is evaluated before, weekly during, and for 3 to 12 months after alefacept +/- narrowband UVB treatment.

Not Applicable
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Drug: Alefacept (drug)
    alefaceptgiven iv
    Other Name: Amevive
  • Procedure: Narrowband UVB phototherapy
Not Provided
Legat FJ, Hofer A, Wackernagel A, Salmhofer W, Quehenberger F, Kerl H, Wolf P. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol. 2007 Aug;143(8):1016-22.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
September 2004
June 2004   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Moderate to severe plaque-type psoriasis;
  • disease duration for more than 6 months
  • PASI above 10.

Exclusion Criteria:

  • age < 18 years;
  • pregnancy or lactation;
  • presence of a dysplastic nevus syndrome;
  • photosensitive skin disease;
  • autoimmune disease;
  • severe renal or hepatic disease;
  • presence or history of malignant skin tumors;
  • presence of antinuclear antibodies;
  • history of previous treatments with arsenic, methotrexate, or x-rays;
  • within the last 4 weeks before enrollment into the study, UVB or PUVA treatment, immunosuppressive/-modulating drugs (such as corticosteroids, cyclosporine, and biologics such as infliximab, etanercept or efalizumab).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Peter Wolf, MD, Principal Investigator, Medical University of Graz, Austria
Medical University of Graz
Not Provided
Principal Investigator: Peter Wolf, MD Research Unit for Photodermatology, Department of Dermatology, Medical University Graz
Medical University of Graz
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP